<DOC>
	<DOC>NCT02874664</DOC>
	<brief_summary>Study to evaluate the effect of rovalpituzumab tesirine on cardiac ventricular repolarization in subjects with small cell lung cancer (SCLC).</brief_summary>
	<brief_title>A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>Histologically or cytologically confirmed extensivestage smallcell lung cancer (SCLC). Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. Adequate hematologic and organ function as confirmed by laboratory values Clinically significant cardiac abnormalities including QRS duration of &gt;120 msec; QTcF &gt;470 msec for women and &gt;450 msec for men; Abnormal cardiac rhythm; Clinically significant cardiac valve abnormality; Documented history of left ventricular ejection fraction &lt;0.30 within 6 months; Permanent pacemaker or automatic implantable cardioverter defibrillator; History of torsades de pointes, congenital long QT syndrome, or family history of long QT syndrome or sudden death Recent or ongoing serious infection Women who are pregnant or breastfeeding Prior exposure to a pyrrolobenzodiazepine (PBD)based drug, prior participation in a rovalpituzumab tesirine clinical trial, or known hypersensitivity to rovalpituzumab tesirine or excipient contained in the drug formulation.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>